A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 06 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov.
- 03 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov record.
- 23 Feb 2014 New trial record